Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Sep-23
- 20-Jun-24
- 18-Jul-24
- 15-Aug-24
- 12-Sep-24
Select bar for recommendation details.
Recommendations | 12-Sep-24 | |
---|---|---|
Buy | 7 | |
Outperform | 15 | |
Hold | 8 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 24 analysts offering 12 month price targets for Alnylam Pharmaceuticals, Inc. have a median target of 295.50, with a high estimate of 400.00 and a low estimate of 160.50. The median estimate represents a 8.18% increase from the last price of 273.15.
High | 46.4% | 400.00 |
Med | 8.2% | 295.50 |
Low | -41.2% | 160.50 |
Earnings history & estimates in USD
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate | +63.86% |
Average growth rate | +11.12% |
More ▼
Revenue history & estimates in USD
Average growth rate | +34.99% |
Average growth rate | +73.67% |
More ▼